Skip to main content

Monkeypox

5
Pipeline Programs
6
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
0
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 7 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
4 programs
2
1
MVA-BN vaccinePhase 4Vaccine1 trial
JYNNEOSPhase 21 trial
JYNNEOSPhase 21 trial
Ocular Complications of Mpox in the Democratic Republic CongoN/A1 trial
Active Trials
NCT06579885Completed320Est. Aug 2025
NCT05512949Completed229Est. Feb 2025
NCT05740982Completed450Est. Aug 2024
+1 more trials
Alliance Pharmaceuticals
1 program
1
Tecovirimat Oral CapsulePhase 41 trial
Active Trials
NCT06156566Recruiting150Est. Aug 2026
BioNTech
BioNTechCA - San Diego
1 program
1
BNT166aPhase 1/21 trial
Active Trials
NCT05988203Completed96Est. Mar 2026
Bavarian Nordic
Bavarian NordicDenmark - Kvistgard
1 program
Blood drawN/A1 trial
Active Trials
NCT03745131Completed120Est. Nov 2019
Nordic Pharma
Nordic PharmaFrance - Paris
1 program
Blood drawN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Alliance PharmaceuticalsTecovirimat Oral Capsule
Allergy TherapeuticsMVA-BN vaccine
Allergy TherapeuticsJYNNEOS
Allergy TherapeuticsJYNNEOS
BioNTechBNT166a
Allergy TherapeuticsOcular Complications of Mpox in the Democratic Republic Congo
Bavarian NordicBlood draw

Clinical Trials (7)

Total enrollment: 1,865 patients across 7 trials

NCT06156566Alliance PharmaceuticalsTecovirimat Oral Capsule

European Trial Into Mpox Infection

Start: Aug 2024Est. completion: Aug 2026150 patients
Phase 4Recruiting
NCT05734508Allergy TherapeuticsMVA-BN vaccine

Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC

Start: Mar 2023Est. completion: Jun 2024500 patients
Phase 4Completed
NCT05740982Allergy TherapeuticsJYNNEOS

A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox

Start: Mar 2023Est. completion: Aug 2024450 patients
Phase 2Completed
NCT05512949Allergy TherapeuticsJYNNEOS

Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine

Start: Sep 2022Est. completion: Feb 2025229 patients
Phase 2Completed
NCT05988203BioNTechBNT166a

A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines

Start: Sep 2023Est. completion: Mar 202696 patients
Phase 1/2Completed
NCT06579885Allergy TherapeuticsOcular Complications of Mpox in the Democratic Republic Congo

Ocular Complications of Mpox in the Democratic Republic Congo

Start: Oct 2024Est. completion: Aug 2025320 patients
N/ACompleted
NCT03745131Bavarian NordicBlood draw

Cohort Study of Healthcare Workers Receiving Imvanex®

Start: Oct 2018Est. completion: Nov 2019120 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,865 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.